The University of Texas MD Anderson Cancer Center

Houston, United States mdanderson.org

Overview

The University of Texas MD Anderson Cancer Center is one of the world's foremost cancer treatment and research institutions. It is dedicated to advancing cancer care, research, education, and prevention. As a part of the University of Texas System, it offers a comprehensive range of services for cancer therapy.

Therapeutic areas

OncologyHematologyImmunotherapySurgical OncologyRadiation Therapy

API / Drug Master Files

The University of Texas MD Anderson Cancer Center holds 5 active (7 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • F18-FLUROROTHYMIDINE (F18-FLT) INJECTIONActive2024-11-22
  • 68 GA GALLIUM CHLORIDEActive2019-09-19
  • [64CU]COPPER CHLORIDEActive2018-09-07
  • AP1903 DRUG SUBSTANCEActive2013-08-14
  • RIMIDUCID FOR INJECTIONActive2013-04-30
  • 3'-DEOXY-3'-[F-18] FLUOROTHYMIDINE (18F-FLT) INJECTIONInactive2012-10-26
  • CYCLOTRON-PRODUCED RADIOPHARMACEUTICALSInactive1986-08-22

FDA compliance signals

1 FDA enforcement record linked to this company.

  • 4832022-03-24

    Reprocessing procedures not written or followed

Related companies

Fate Therapeutics, Inc.
United States
Fred Hutchinson Cancer Center
United States
OncoTherapeutics Inc.
USA
Acceleron Pharma Inc.
United States
Acerta Pharma LLC
USA
Acrotech Biopharma, Inc.
United States
Adventris Pharmaceuticals
United States
Allogene Therapeutics, Inc.
United States

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo